Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Clinical/translational cancer immunotherapy

Original research

Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells

Online download statistics by month:

Online download statistics by month: March 2024 to January 2026

	Abstract	Full	Pdf
Mar 2024	468	469	216
Apr 2024	332	335	219
May 2024	344	346	117
Jun 2024	168	169	106
Jul 2024	338	339	88
Aug 2024	111	110	78
Sep 2024	105	105	80
Oct 2024	125	125	90
Nov 2024	131	133	92
Dec 2024	155	157	68
Jan 2025	157	157	77
Feb 2025	280	280	122
Mar 2025	174	174	133
Apr 2025	190	190	98
May 2025	180	180	102
Jun 2025	112	117	57
Jul 2025	1	1	0
Sep 2025	5	5	0
Jan 2026	0	0	1
Total	3376	3392	1744